Wave Life Sciences (NASDAQ: WVE) director Verdine discloses stock sales

Rhea-AI Filing Summary

Wave Life Sciences Ltd. director Gregory L. Verdine reported sales of company stock. On 12/08/2025, he sold 12,020 ordinary shares at a weighted-average price of $13.09 per share and 7,980 ordinary shares at a weighted-average price of $14.05 per share.

The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After these transactions, Verdine directly owned 275,217 ordinary shares of Wave Life Sciences. The price ranges for the sales were $12.75–$13.74 and $13.75–$14.70 per share, respectively.

Insider Trade Summary

Net Seller: 20,000 shares ($269,461)

Net Sell 2 txns

Insider Verdine Gregory L.

Role Director

Sold 20,000 shs ($269K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	12,020	$13.09	$157K
Sale	Ordinary Shares	7,980	$14.05	$112K

Holdings After Transaction: Ordinary Shares — 283,197 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.70 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verdine Gregory L.

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/08/2025		S(1)		12,020	D	$13.09(2)	283,197	D
Ordinary Shares	12/08/2025		S(1)		7,980	D	$14.05(3)	275,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

2. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.70 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price

	/s/ Gregory L. Verdine	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Wave Life Sciences (WVE) disclose in this filing?

The filing reports that director Gregory L. Verdine sold Wave Life Sciences ordinary shares in two transactions on 12/08/2025, totaling 20,000 shares.

How many Wave Life Sciences (WVE) shares did the director sell and at what prices?

Gregory L. Verdine sold 12,020 ordinary shares at a weighted-average price of $13.09 per share and 7,980 ordinary shares at a weighted-average price of $14.05 per share.

How many Wave Life Sciences (WVE) shares does the director still own after the sales?

After the reported transactions, Gregory L. Verdine directly owned 275,217 ordinary shares of Wave Life Sciences Ltd.

Were the Wave Life Sciences (WVE) insider sales made under a Rule 10b5-1 trading plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan that Gregory L. Verdine adopted on March 13, 2025.

What were the price ranges for the Wave Life Sciences (WVE) shares sold by the director?

For the first block, the sale price range was $12.75 to $13.74 per share. For the second block, the range was $13.75 to $14.70 per share.

Is Gregory L. Verdine a director or officer of Wave Life Sciences (WVE)?

The filing identifies Gregory L. Verdine as a director of Wave Life Sciences Ltd., with the reported holdings shown as direct ownership.